DiagnoCure Directors Re-Elected by Shareholders at Annual and Special Meeting of Shareholders
PR Newswire
QUEBEC CITY, April 29, 2013
QUEBEC CITY , April 29, 2013 /PRNewswire/ - DiagnoCure Inc. (TSX: CUR) (OTCQX: DGCRF) is pleased to announce that Dr. Yves Fradet , Dr. Louise Proulx , Mr. Andrew Sheldon , Dr. Jacques Simoneau , and Dr. Vincent R. Zurawski , were re-elected by shareholders at the 2013 annual and special meeting of shareholders, held today in Montreal .
Shareholders also reappointed Ernst & Young as auditors of the company, approved and ratified amendments to the articles of DiagnoCure, approved and ratified the new by-laws of the company - including the advanced notice by-law, and approved all unallocated options under DiagnoCure's stock option plan.
Dr. Yves Fradet , Chairman of the Board stated, "We appreciate the support of our shareholders in re-electing all of DiagnoCure's director nominees. Rest assured, your board and management team will continue to work to enhance and maximize value for shareholders."
"We will continue to be receptive to feedback from all of our shareholders." said Dr. Fradet.
The election results for the Board of directors are as follows:
| For | Withheld | |
| DiagnoCure nominees | ||
| Yves Fradet | 15,064,450 | 11,584,571 |
| Louise Proulx | 15,195,476 | 11,573,041 |
| Andrew J. Sheldon | 15,155,676 | 11,612,841 |
| Jacques Simoneau | 15,194,976 | 11,573,041 |
| Vincent R. Zurawski | 15,167,576 | 11,600,941 |
| Dissident nominees | ||
| Pierre Dozois | 5,385,250 | 22,797,322 |
| Paul Guay | 5,385,250 | 22,797,322 |
| Hans Mäder | 5,385,250 | 22,797,322 |
About DiagnoCure
DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation that develops and commercializes high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions. In 2008, the Corporation launched a colorectal cancer staging test through its U.S. CLIA laboratory. PrevistageTM GCC is currently available for licensing. The Corporation has granted a worldwide exclusive license to Gen-Probe, now a wholly-owned subsidiary of Hologic Inc. operating as Hologic Gen-Probe, for the development and commercialization of a prostate cancer test using PCA3, DiagnoCure's proprietary molecular biomarker. Hologic Gen-Probe's PROGENSA® PCA3 test is commercialized in Europe under CE mark and is approved for commercialization in Canada and the United States . For more information, please visit www.diagnocure.com .
Forward?looking statements
This release may contain forward?looking statements that involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ materially from those expected. Forward-looking statements can be identified by the use of the conditional or forward-looking terminology such as "anticipates", "assumes", "believes", "estimates", "expects", "intend", "may", "plans", "projects", "should", "will", or the negative thereof or other variations thereon. Forward-looking statements also include any other statements that do not refer to historical facts. All such forward-looking statements are made pursuant to the "safe-harbour" provisions of applicable Canadian securities laws. By their very nature, forward?looking statements are based on expectations and hypotheses and also involve risks and uncertainties, known and unknown, many of which are beyond DiagnoCure's control. Forward-looking statements are presented for the purpose of assisting investors and others in understanding certain key elements of the Corporation's current objectives, strategic priorities, expectations and plans, and in obtaining a better understanding of the Corporation's business and anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes and that they should not place undue reliance on these forward?looking statements. For instance, any forward-looking statements regarding the outcome of research and development projects, clinical studies and future revenues, including those related to PROGENSA® PCA3, are based on management expectations and such outcome may vary materially depending on global political and economic conditions, dependence on collaboration partners, uncertainty of healthcare reimbursement, and marketing and distribution challenges. In addition, the reader is referred to the applicable general risks and uncertainties described in DiagnoCure's most recent Annual Information Form under the heading "Risk Factors". DiagnoCure undertakes no obligation to publicly update or revise any forward?looking statements contained herein unless required by the applicable securities laws and regulations.
SOURCE DiagnoCure inc.
